Previously, the primary endpoint results of the NRG-LU005 (NCT03811002) study assessing the addition of the immunotherapy drug atezolizumab (Tecentriq) to standard-of-care concurrent chemoradiation for limited-stage small-cell lung cancer were reported at the American Society for Radiation Oncology 2024 Annual Meeting. Those results showed that adding atezolizumab did not improve overall survival (OS) for this patient population.
A newly developed radiotheranostic pair, 68Ga/177Lu-NYM096, can identify tumors and effectively deliver targeted radiotherapy to patients with metastatic clear cell renal cell carcinoma (ccRCC). Using a small-molecule compound, the new approach helps mitigate toxicity issues common with treatment, offering a safe and feasible strategy for those with end-stage disease. This research was published in the September issue of The Journal of Nuclear Medicine.
When a child has symptoms that could be pneumonia, doctors often listen to the child's lungs with a stethoscope to help make a diagnosis. But a new national study led by physician-scientists at Ann & Robert H. Lurie Children's Hospital of Chicago and PECARN finds that doctors may not always hear or interpret the same things when examining the same child, illustrating limitations of the physical examination.
A more than a decade-long medical trial has opened the way for potentially life-saving treatment options for patients with mild-to-moderate heart conditions. Internationally recognized cardiac expert Flinders University Professor Joseph Selvanayagam, from Adelaide's Heart & Vascular, presented his findings at the European Society of Cardiology Congress (ESC 2026) in Munich on Friday. The breakthrough has also been published in JAMA.
Nurses and physicians often recognize what kind of care a patient deserves at a given moment, whether it is more time at the bedside, a change in pain management or a detailed conversation about the goals of a specific treatment. However, these health care professionals sometimes find themselves unable to follow through because of external factors, ranging from understaffing and resource shortages to institutional policies and regulations.
The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in inflammation-related biomarkers through six months in patients with chronic kidney disease and elevated inflammatory risk associated with heart disease.
Researchers at LSU's Pennington Biomedical Research Center have identified a previously underappreciated role for tiny structures inside cells called peroxisomes in protecting insulin and maintaining the health and maturity of insulin-producing pancreatic beta cells.